GC Biopharma’s third-quarter operating profit rose 68.5 percent from a year earlier to 49.2 billion won ($36.7 million), driven by stronger sales of higher-margin products and reduced losses at its U.S. subsidiary.
On Monday, the Korean company said it reported preliminary consolidated revenue of 522.1 billion won and net profit of 208.5 billion won for the third quarter of 2026 in a regulatory filing on Oct. 31. Net profit soared 1,051.9 percent from a year earlier.
Seasonally strong influenza vaccine sales contributed to improved profitability, while sales carried over from the second quarter provided an additional boost.
Alyglo, an intravenous immunoglobulin product, generated about $46 million in third-quarter sales, following $51 million in the first half, bringing cumulative sales to $97 million and moving the company closer to its full-year target of $150 million.
Net profit also benefited from an upfront payment related to the May sale of its U.S. affiliate, Curevo Vaccine, to Eli Lilly. The payment was recognized in the third quarter. The transaction could generate additional revenue through contract manufacturing opportunities and sales-based royalties if Curevo's pipelin...